Portal de Periódicos da CAPES

Adrenal tumors inBRCA1/BRCA2 mutation carriers

2001; Wiley; Volume: 98; Issue: 3 Linguagem: Inglês

10.1002/1096-8628(20010122)98

1096-8628

Frieda Barak, Ronit Shiri-Svredlov, Revital Bruchim-Bar Sade, Anna Kruglikova, Eitan Friedman, David Ben‐Dor, Iris Goldberg,

DNA Repair Mechanisms

American Journal of Medical GeneticsVolume 98, Issue 3 p. 277-279 Letter to the Editor: Letter to the Editor Adrenal tumors in BRCA1/BRCA2 mutation carriers Frieda Barak, Frieda Barak Department of Oncology, Barzilai Medical Center, Ashkelon, IsraelSearch for more papers by this authorRonit Shiri-Svredlov, Ronit Shiri-Svredlov The Susanne Levy Gertner, Oncogenetics Unit, Danek Gertner Institute of Genetics, Sheba Medical Center, Tel-Hashomer, Sackler school of Medicine, IsraelSearch for more papers by this authorRevital Bruchim-Bar Sade, Revital Bruchim-Bar Sade The Susanne Levy Gertner, Oncogenetics Unit, Danek Gertner Institute of Genetics, Sheba Medical Center, Tel-Hashomer, Sackler school of Medicine, IsraelSearch for more papers by this authorAnna Kruglikova, Anna Kruglikova The Susanne Levy Gertner, Oncogenetics Unit, Danek Gertner Institute of Genetics, Sheba Medical Center, Tel-Hashomer, Sackler school of Medicine, IsraelSearch for more papers by this authorEitan Friedman, Corresponding Author Eitan Friedman [email protected] The Susanne Levy Gertner, Oncogenetics Unit, Danek Gertner Institute of Genetics, Sheba Medical Center, Tel-Hashomer, Sackler school of Medicine, IsraelThe Susanne Levy Gertner Oncogenetics Unit, Danek Gertner Institute of Genetics, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel.Search for more papers by this authorDavid Ben-Dor, David Ben-Dor Department of Pathology, Barzilai Medical Center, Ashkelon, IsraelSearch for more papers by this authorIris Goldberg, Iris Goldberg Department of Pathology, Sheba Medical Center, Tel-Hashomer, Sackler school of Medicine, IsraelSearch for more papers by this author Frieda Barak, Frieda Barak Department of Oncology, Barzilai Medical Center, Ashkelon, IsraelSearch for more papers by this authorRonit Shiri-Svredlov, Ronit Shiri-Svredlov The Susanne Levy Gertner, Oncogenetics Unit, Danek Gertner Institute of Genetics, Sheba Medical Center, Tel-Hashomer, Sackler school of Medicine, IsraelSearch for more papers by this authorRevital Bruchim-Bar Sade, Revital Bruchim-Bar Sade The Susanne Levy Gertner, Oncogenetics Unit, Danek Gertner Institute of Genetics, Sheba Medical Center, Tel-Hashomer, Sackler school of Medicine, IsraelSearch for more papers by this authorAnna Kruglikova, Anna Kruglikova The Susanne Levy Gertner, Oncogenetics Unit, Danek Gertner Institute of Genetics, Sheba Medical Center, Tel-Hashomer, Sackler school of Medicine, IsraelSearch for more papers by this authorEitan Friedman, Corresponding Author Eitan Friedman [email protected] The Susanne Levy Gertner, Oncogenetics Unit, Danek Gertner Institute of Genetics, Sheba Medical Center, Tel-Hashomer, Sackler school of Medicine, IsraelThe Susanne Levy Gertner Oncogenetics Unit, Danek Gertner Institute of Genetics, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel.Search for more papers by this authorDavid Ben-Dor, David Ben-Dor Department of Pathology, Barzilai Medical Center, Ashkelon, IsraelSearch for more papers by this authorIris Goldberg, Iris Goldberg Department of Pathology, Sheba Medical Center, Tel-Hashomer, Sackler school of Medicine, IsraelSearch for more papers by this author First published: 12 January 2001 https://doi.org/10.1002/1096-8628(20010122)98:3 3.0.CO;2-QCitations: 7Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T. 1997. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60: 505–514. BCLC database. http://ruly70.medfac.leidenuniv.nl/∼devilee/BCLC/b1other.htm or /b2other BIC database. http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/Member/index.html Brüchim Bar-Sade R, Kruglikova A, Modan B, Gak E, Hirsh-Yechezkel G, Theodor L, Novikov I, Gershoni-Baruch R, Risel S, Papa MZ, Ben-Baruch G, Friedman E. 1998. The 185delAG BRCA1 mutation originated before the dispersion of Jews in the Diaspora and is not limited to Ashkenazim. Hum Mol Genet 7: 801–806. Easton DF, Bishop DT, Ford D, Cockford GP, and the Breast Cancer Linkage Consortium: 1993. Genetic linkage analysis in familial breast and ovarian cancer. Am J Hum Genet 52: 718–722. Ford D, Easton D, Bishop D, Narod S, Goldgar D, and the Breast Cancer Linkage Consortium. 1994. Risks of cancer in BRCA1-mutation carriers. Lancet 343: 692–695. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Thomas A. 1998. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16: 2417–2425. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. 1999. The prevalence of common BRCA1 and BRCA2 Mutations among Ashkenazi Jews. Am J Hum Genet 64: 963–970. Israel cancer Registry, Ministry of Health, Publication 207, Jerusalem, 1998. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harsman K, Tavtigian S, Liu Q, Cochran C, Bennet LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Pelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wessman R, Kamb A, Skolnick MH. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71. Modan B, Gak E, Hirsch G, Bar-Sade Brucim R, Theodor L, Lubin F, Ben-Baruch G, Beller U, Fishman A, Dgani R, Menczer J, Papa MZ, Friedman E. 1996. High frequency of the 185delAG mutation in ovarian cancer in Israel. JAMA 276: 1823–1825. Rohlfs EM, Learning WG, Friedman KJ, Couch FJ, Weber BL, Silverman LM. 1997. Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem 43: 24–29. Szabo CI, King MC. 1997. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60: 1013–1020. Tavitigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, LeBlanc JF, Mitchell JT, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swensen J, Teng D, Thomas A, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AKC, Shizuya H, Eyfjord JE, Cannon-Albright L, LaBrie F, Skolnick MH, Weber B, Kamb A, Goldgar DE. 1996. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12: 333–337. Wagner T, Stoppa-Lyonnet D, Fleischmann E, Muhr D, Pages S, Sandberg T, Caux V, Moeslinger R, Langbauer G, Borg A, Oefner P. 1999. Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 62: 369–376. Citing Literature Volume98, Issue322 January 2001Pages 277-279 ReferencesRelatedInformation